Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

Bristol Myers Squibb trades at a low 9.7x forward P/E ratio due to upcoming patent expirations on blockbuster drugs Opdivo and Eliquis, which will face generic competition. However, the article argues this presents a buying opportunity for long-term investors, as patent losses are normal in pharma, the company has new drugs in development, and it offers an attractive 4.1% dividend yield with a strong history of dividend growth.